NXGL vs BFRI vs DERM vs PRGO vs MCK

For growth investors, NEXGEL, Inc.

(NXGL) is the stronger pick with 112. 5% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.

4%, compared to -98. 7% for Biofrontera Inc. (BFRI). Over 10 years, the gap is even starker: MCK returned +339. 0% versus BFRI's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Journey Medical Corporation's 1. 78β — meaning DERM is approximately -10971% more volatile than MCK relative to the S&P 500. On balance sheet safety, NEXGEL, Inc. (NXGL) carries a lower debt/equity ratio of 46% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NEXGEL, Inc.

(NXGL) is pulling ahead at 112. 5% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Biofrontera Inc. grew EPS 100. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, NXGL leads at 77. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

McKesson Corporation (MCK) is the more profitable company, earning 1.

2% net margin versus -37. 8% for NEXGEL, Inc. — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -40. 9% for NXGL. At the gross margin level — before operating expenses — BFRI leads at 75. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 69. 9x for Journey Medical Corporation — 64. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

In this comparison, PRGO (9.

8% yield), MCK (0. 4% yield) pay a dividend. NXGL, BFRI, DERM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02), +339. 0% 10Y return). Journey Medical Corporation (DERM) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCK: +339. 0%, DERM: -46. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NXGL is a small-cap high-growth stock; BFRI is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; MCK is a mid-cap quality compounder stock. PRGO pays a dividend while NXGL, BFRI, DERM, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.